GoldenGolden
Advanced Search
Atara Biotherapeutics

Atara Biotherapeutics

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company that is pioneering the development of transformative therapies for patients who are with serious diseases that include hematologic cancers, solid tumors and autoimmune diseases.

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company that is pioneering the development of transformative therapies for patients who are with serious diseases that include hematologic cancers, solid tumors and autoimmune diseases.

Atara aims to deliver treatments to patients with unmet medical need by leveraging its novel allogeneic EBV T-cell platform.

Its platform intends to leverage the biology of EBV T cells to channel the power of immune system and has the potential of treating a broad range of diseases.

Atara is applying its platform to build a robust pipeline with the goal of developing treatments that enhance the quality and longevity of the lives of patients.

Timeline

January 2014
Atara Biotherapeutics raises a $52,000,000 series B round from Alexandria Venture Investments, Amgen Ventures, Baupost Group, Celgene, DAG Ventures, Domain Associates, EcoR1 Capital and Kleiner Perkins Caufield & Byers.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Yereth Rosen
May 19, 2021
news.yahoo.com
In the boreal forests of the planet's far north, where the climate is warming faster than almost anywhere else in the world, some wildfires are surviving...
Alex Keown
May 14, 2021
BioSpace
Biopharma and life sciences companies strengthen their leadership teams and boards with Movers & Shakers.
BioSpace
May 10, 2021
BioSpace
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today named cell therapy and oncology expert Cokey Nguyen, Ph.D. as Chief Scientific Officer.
Alex Keown
April 9, 2021
BioSpace
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Fraiser Kansteiner
April 9, 2021
FierceBiotech
Bluebird's former CMO has landed at Tessera three weeks after flying the nest. Thermo Fisher veteran Zhang has landed the CEO spot at genomics up-and-comer Mission Bio. Medable, enjoying a pandemic boost to its decentralized trial services, has tapped Pamela Tenaerts, M.D., as its chief scientific officer.
Ben Adams
December 7, 2020
FierceBiotech
German pharma Bayer is moving into cell therapy R&D with its latest pact focusing on tough-to-treat lung cancers with Atara Biotherapeutics.
May 15, 2020
BioSpace
Atara Biotherapeutics Announces Presentation of Late-Breaking Preclinical Data on ATA2271, a Next-Generation Autologous CAR T Immunotherapy Targeting Mesothelin, at the American Association for Cancer Research Virtual Annual Meeting II 2020 - read this article along with other careers information, tips and advice on BioSpace
BioSpace
May 14, 2020
BioSpace
Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune disease, named cell therapy and oncology expert Jakob Dupont, M.D. as Executive Vice President, Global Head of Research and Development.
BioSpace
May 11, 2020
BioSpace
Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune diseases, announced the appointment of immunology and cell & gene therapy expert Maria Grazia Roncarolo, MD, to the Board of Directors.
BioSpace
April 2, 2020
BioSpace
Atara Biotherapeutics, Inc. is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases.
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.